KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Gains from Sales and Divestitures (2019 - 2025)

Adaptive Biotechnologies' Gains from Sales and Divestitures history spans 7 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 29.84% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, up 29.84%, while the annual FY2025 figure was $3.4 million, 29.84% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $3.4 million at Adaptive Biotechnologies, up from $247117.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $3.4 million in Q4 2025 and bottomed at $12500.0 in Q2 2021.
  • The 5-year median for Gains from Sales and Divestitures is $1.2 million (2023), against an average of $1.3 million.
  • The largest annual shift saw Gains from Sales and Divestitures soared 1524.73% in 2022 before it plummeted 89.76% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $18750.0 in 2021, then skyrocketed by 1524.73% to $304637.0 in 2022, then skyrocketed by 394.64% to $1.5 million in 2023, then surged by 71.73% to $2.6 million in 2024, then increased by 29.84% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Gains from Sales and Divestitures are $3.4 million (Q4 2025), $247117.0 (Q3 2025), and $3.1 million (Q2 2025).